Q&A: Market access strategies for innovative drugs

Over the last two decades, biopharmaceutical manufacturers have faced new obstacles in the market access of their products. The increasing development costs, shifting influences between stakeholders, and growing pharmaceutical competition are just some of the factors that are reshaping pharma’s market access. In an increasingly cost-conscious healthcare environment, pharma companies must make a thorough case for not only the clinical, but also the economic value of their products.

This webinar will have expert speakers sharing their perspectives on the dynamics and challenges of market access for innovative biopharmaceutical products.

When: 06.10.2020 | 14:00 – 15:00 CEST
    Where: Online


  • Market access as a key enabler for commercial success
  • How to manage market access for products in early development
  • Factors influencing price and reimbursement/funding for biopharma products
  • Gaining market access in a challenging European environment



Leonildo Delgado, Manager Innovation & Sourcing BaseLaunch, Basel Area Business & Innovation


– Nicolas Gimenez-Stamminger, Senior Manager Life Sciences Strategy, KPMG Switzerland
– Peter Mozerov, Manager Life Sciences Strategy, KPMG Switzerland
– Morteza Yazdani, Market Access Strategy Leader – Oncology, Bayer Pharmaceuticals


Participation in the event is free, but registration is required before 05.10.2020. You will receive the link to the webinar after your registration has been confirmed.  REGISTER FOR EVENT


Our partner: KPMG Switzerland